Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.

@article{Bhosle2013TreatmentWG,
  title={Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.},
  author={Jaishree Bhosle and Konstantinos Kiakos and Andrew C. G. Porter and Jenny Wu and Andreas Makris and John A. Hartley and Daniel Hochhauser},
  journal={Molecular cancer therapeutics},
  year={2013},
  volume={12 12},
  pages={2897-908}
}
The EGF receptor (EGFR) is therapeutically targeted by antibodies and small molecules in solid tumors including lung, colorectal, and breast cancer. However, chemotherapy remains important, and efforts to improve efficacy through combination with targeted agents is challenging. This study examined the effects of short and long durations of exposure to the EGFR- and HER2-targeted tyrosine kinase inhibitors (TKI) gefitinib and lapatinib, on induction of cell death and DNA damage by topoisomerase… CONTINUE READING
5 Citations
53 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 53 references

Similar Papers

Loading similar papers…